Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy-Reference-Cited by-同舟云学术

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy

Published:2019-05-21 Issue:8 Volume:94 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Chow Victor A.¹²³^ORCID,Gopal Ajay K.¹²³^ORCID,Maloney David G.¹²³,Turtle Cameron J.¹²³,Smith Stephen D.¹²³^ORCID,Ujjani Chaitra S.¹²³,Shadman Mazyar¹²³,Cassaday Ryan D.¹²⁴,Till Brian G.¹²³,Tseng Yolanda D.²⁵,Warren Edus H.¹²³^ORCID,Shustov Andrei R.¹²⁴,Menon Manoj P.¹⁴,Bhark Sandra²⁶,Acharya Utkarsh H.¹²³⁷,Mullane Erin²,Hannan Lindsay M.¹²³,Voutsinas Jenna M.⁸,Gooley Ted A.¹⁸,Lynch Ryan C.¹²³

Affiliation:

1. Clinical Research DivisionFred Hutchinson Cancer Research Center Seattle Washington

2. Seattle Cancer Care Alliance Seattle Washington

3. Department of Medicine, Division of Medical OncologyUniversity of Washington Seattle Washington

4. Department of Medicine, Division of HematologyUniversity of Washington Seattle Washington

5. Department of Radiation OncologyUniversity of Washington Seattle Washington

6. Fred Hutchinson Cancer Research Center, Public Health DivisionFred Hutchinson Cancer Research Center Seattle Washington

7. Department of Medical Oncology, Divisions of Hematologic Malignancies and Cellular TherapyDana Farber Cancer Institute Boston Massachusetts

8. Swedish Cancer Institute Seattle Washington

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25505

Reference8 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

3. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

4. Translating anti‐CD19 CAR T‐cell therapy into clinical practice for relapsed/refractory diffuse large B‐cell lymphoma;Chow VA;Blood,2018

5. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy;Blood Advances;2024-09-24

2. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09

3. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

4. The basic biology of NK cells and its application in tumor immunotherapy;Frontiers in Immunology;2024-08-16

5. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis;Blood;2024-08-08